Repare Therapeutics Inc (RPTX)

$1.20 0.00 (N/A)
Market Cap 51.01M
Revenue (ttm) 53.48M
Net Income (ttm) -84.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -158.36%
Debt to Equity Ratio 0.00
Volume 418,191
Avg Vol 284,524
Day's Range N/A - N/A
Shares Out 42.51M
Stochastic %K 72%
Beta 0.91
Analysts Sell
Price Target $5.00

Latest News on RPTX

Repare Therapeutics Announces Leadership Transitions

Mar 31, 2025, 4:39 PM EDT - 21 days ago

Repare Therapeutics Announces Leadership Transitions

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 7, 2025, 4:05 PM EST - 6 weeks ago

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 7:05 AM EST - 7 weeks ago

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Jan 9, 2025, 4:05 PM EST - 3 months ago

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Dec 13, 2024, 12:09 PM EST - 4 months ago

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Dec 12, 2024, 4:20 PM EST - 4 months ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Dec 10, 2024, 4:05 PM EST - 4 months ago

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Nov 12, 2024, 7:05 AM EST - 5 months ago

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 7:05 AM EST - 5 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Oct 23, 2024, 6:05 AM EDT - 6 months ago

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Oct 14, 2024, 7:05 AM EDT - 6 months ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Sep 30, 2024, 4:05 PM EDT - 7 months ago

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Sep 23, 2024, 7:05 AM EDT - 7 months ago

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Sep 13, 2024, 7:00 AM EDT - 7 months ago

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 30, 2024, 6:13 PM EDT - 8 months ago

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Aug 28, 2024, 4:05 PM EDT - 8 months ago

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 27, 2024, 7:05 AM EDT - 8 months ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 9 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Jun 26, 2024, 10:30 AM EDT - 10 months ago

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Jun 12, 2024, 7:00 AM EDT - 11 months ago

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Jun 10, 2024, 7:05 AM EDT - 11 months ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Jun 4, 2024, 4:05 PM EDT - 11 months ago

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 11 months ago

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

May 29, 2024, 7:05 AM EDT - 11 months ago

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Repare Therapeutics Appoints Steven H. Stein, M.D.

Apr 26, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Appoints Steven H. Stein, M.D.

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Mar 21, 2024, 10:00 AM EDT - 1 year ago

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Feb 15, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Repare Therapeutics to Regain Global Rights to Camonsertib

Feb 12, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics to Regain Global Rights to Camonsertib

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

Jan 25, 2024, 7:00 AM EST - 1 year ago

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Jan 8, 2024, 7:00 AM EST - 1 year ago

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Jan 4, 2024, 4:10 PM EST - 1 year ago

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Jan 4, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Dec 29, 2023, 4:05 PM EST - 1 year ago

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

Nov 15, 2023, 7:00 AM EST - 1 year ago

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 7:00 AM EST - 1 year ago

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

Nov 7, 2023, 7:00 AM EST - 1 year ago

Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

Repare: Potential Of Camonsertib With Several Shots On Goal

Nov 6, 2023, 7:43 PM EST - 1 year ago

Repare: Potential Of Camonsertib With Several Shots On Goal

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Oct 13, 2023, 9:40 AM EDT - 1 year ago

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Repare Therapeutics: A Compelling Bet On Synthetic Lethality

Oct 3, 2023, 9:00 AM EDT - 1 year ago

Repare Therapeutics: A Compelling Bet On Synthetic Lethality

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 3, 2023, 7:00 AM EDT - 1 year ago

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 7:00 AM EDT - 1 year ago

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics